Sayan, Cemile DayanganTulmac, Ozlem BanuKaraca, GokhanOzkan, Zehra SemaYalcin, SelimDevrim, TubaBadem, Nermin Dindar2020-06-252020-06-252018closedAccess0951-35901473-0766https://doi.org/10.1080/09513590.2017.1395836https://hdl.handle.net/20.500.12587/7567Ozkan, Zehra Sema/0000-0001-9185-3663The aim of this study is to investigate whether erythropoietin (EPO) can reduce the ovarian damage of cisplatin or not. Thirty, female, Wistar-Albino rats were used in the study. Control group (N=10): Intraperitoneal saline infusion, Cisplatin group (N=10): Intraperitoneal 7mg/kg cisplatin, Cisplatin+EPO group (N=10): Intraperitoneal 7mg/kg cisplatin and subcutaneous 200IU/kg/day EPO. Serum AMH concentrations were measured by enzyme-linked immunosorbent assay kit of AMH. Follicular counts were evaluated according to mean diameter of the follicles. Ovarian damage; including follicular cell degeneration, vascular congestion, hemorrhage, and inflammation was scored histologically using a graduated scale. Posttreatment AMH levels of cisplatin group were significantly lower than control and cisplatin+EPO groups. In cisplatin group, there was a significant decrement in posttreatment AMH level compared to pretreatment AMH level. The total damage score of cisplatin group was significantly higher than scores of control and cisplatin+EPO groups. The mean primordial follicle counts of control and cisplatin+EPO groups were significantly higher than that of cisplatin group (p=.007 and p=.003). The results of this study revealed that EPO administration to cisplatin chemotherapy could ameliorate the ovarian damage. Erythropoietin administration to chemotherapeutic agents might suggest to protect ovarian failure and infertility.eninfo:eu-repo/semantics/closedAccessCisplatinerythropoietinovaryAMHArticle34430931310.1080/09513590.2017.13958362-s2.0-8503266668529084473Q2WOS:000428813900013Q4